WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD 45.14
-0.58 (-1.27%)
Aug 14, 2026, 4:08 PM HKT
WuXi Biologics Stock Forecast
Stock Price Forecast
According to 25 analysts polled by S&P Global, WuXi Biologics stock has a consensus rating of "Buy" and an average price target of $47.05. The average 1-year stock price forecast is 4.23% higher than the current stock price, while the lowest is $30.73 (-31.92%) and the highest is $78.79 (+74.55%).
Price Target: $47.05 (+4.23%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for WuXi Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 16 | 17 | 17 | 17 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 4 | 5 | 4 | 4 | 4 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 26 | 27 | 25 | 26 | 26 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Buy Maintains $47.00 | Buy | Maintains | $47.00 | +4.12% | Aug 3, 2026 |
Unknown Analyst Nomura No rating | Nomura | Buy Maintains $51.38 | Buy | Maintains | $51.38 | +13.82% | Jul 24, 2026 |
Unknown Analyst SDIC Securities No rating | SDIC Securities | Buy Maintains $47.44 | Buy | Maintains | $47.44 | +5.10% | Jul 17, 2026 |
Unknown Analyst CLSA No rating | CLSA | Buy Maintains $51.90 | Buy | Maintains | $51.90 | +14.98% | Jul 10, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $50.00 | Buy | Maintains | $50.00 | +10.77% | Jul 9, 2026 |
Financial Forecast
Revenue This Year
25.28B
from 21.79B
Increased by 16.00%
Revenue Next Year
29.75B
from 25.28B
Increased by 17.69%
EPS This Year
1.43
from 1.33
Increased by 7.30%
EPS Next Year
1.73
from 1.43
Increased by 21.45%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.